Trial · NCT07893470
Transcutaneous Spinal Cord Stimulation for Neurorehabilitation After Spinal Cord Injury
NCT07893470, Not applicable, Not yet recruiting, Ernesto Losavio
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Transcutaneous Spinal Cord Stimulation for Neurorehabilitation After Spinal Cord Injury. Trials, record NCT07893470. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07893470
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Transcutaneous Spinal Cord Stimulation for Neurorehabilitation After Spinal Cord Injury
- NCT number
- NCT07893470
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 20 participants, estimated
- Lead sponsor
- Ernesto Losavio
- Conditions
- Spinal Cord Injury
- Interventions
- ExaStim® Transcutaneous Spinal Cord Stimulation, Conventional Rehabilitation
- First posted
- 2026-10-26
- Last updated
- 2026-10-26
Source ClinicalTrials.gov
Registered outcomes19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Finger Strength | Immediately before and immediately after each stimulation session, twice weekly for 4 weeks | Finger flexion and extension strength will be assessed using the AMADEO robotic device and expressed in Newtons (N). |
| Primary | Finger Range of Motion | Immediately before and immediately after each stimulation session, twice weekly for 4 weeks | Finger range of motion (ROM) will be assessed using the AMADEO robotic device and expressed as a percentage (%). |
| Primary | Finger Muscle Tone | Immediately before and immediately after each stimulation session, twice weekly for 4 weeks | Finger muscle tone will be assessed using the AMADEO robotic device by measuring passive resistance during finger movement, expressed in Newtons (N). |
| Primary | Finger Spasticity | Immediately before and immediately after each stimulation session, twice weekly for 4 weeks | Finger spasticity will be assessed using the AMADEO robotic device at three different movement velocities. |
| Primary | Hand Grip Strength | Immediately before and immediately after each stimulation session, twice weekly for 4 weeks | Hand grip strength will be measured using a digital hand grip dynamometer and expressed in kilograms (kg). |
| Primary | Muscle Activation | Immediately before and immediately after each stimulation session, twice weekly for 4 weeks | Muscle activation during motor tasks will be assessed using surface electromyography (sEMG). Raw electromyographic signals will be recorded in microvolts (µV). |
| Secondary | Muscle Strength | Baseline and end of the 4-week intervention period. | Muscle strength will be assessed using the Medical Research Council (MRC) scale, which grades muscle strength from 0 (no muscle contraction) to 5 (normal muscle strength). |
| Secondary | Spasticity | Baseline and end of the 4-week intervention period. | Spasticity will be assessed using the Modified Ashworth Scale (MAS), an ordinal scale ranging from 0 (no increase in muscle tone) to 4 (affected part rigid in flexion or extension), including an intermediate 1+ category. |
| Secondary | Upper Limb Functional Performance | Baseline and end of the 4-week intervention period. | Upper limb functional performance will be assessed using the Van Lieshout Test (VLT), in which individual tasks are scored from 0 (unable to perform the task) to 5 (independent and optimal performance). |
| Secondary | Hand Grip Strength | Baseline and end of the 4-week intervention period. | Hand grip strength will be measured using a digital hand grip dynamometer and expressed in kilograms (kg). |
1 to 10 of 19Source ClinicalTrials.gov
See all 19 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07893470
GET https://conductscience.org/api/trials/v1/NCT07893470/registered